Healthcare Services

Ophthalmoplegia Market Expected to Record Steady Growth and Approach $2.95 Billion by 2030

April 3, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Ophthalmoplegia Market Over The 2026–2030 Period?

The ophthalmoplegia market has seen rapid expansion in recent years. It is anticipated to grow from $1.84 billion in 2025 to $2.03 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. This growth witnessed in the past period can be attributed to several factors, including the limited available treatment options for ophthalmoplegia, a lack of specialized ophthalmic centers, low public awareness regarding eye muscle disorders, the reliance on conventional surgical approaches, and an increasing prevalence of neuromuscular disorders that impact the eyes.

The ophthalmoplegia market is anticipated to experience substantial expansion over the upcoming years, with projections indicating it will reach $2.95 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 9.8%. Factors contributing to this growth during the forecast period include developments in minimally invasive surgical methods, an increase in targeted pharmacological treatments, the growing adoption of tele-ophthalmology, more government programs for managing rare eye disorders, and the expansion of personalized medicine and genetic diagnostics. Key trends anticipated during this period involve a greater uptake of minimally invasive surgeries for ophthalmoplegia, an increased application of targeted drug treatments for eye muscle conditions, an intensified emphasis on early diagnosis and screening, the broadening of tele-ophthalmology for patient surveillance, and heightened awareness regarding neurological and muscular conditions affecting the eyes.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=22081&type=smp

Which Major Factors Are Driving The Expansion Of The Ophthalmoplegia Market?

The ophthalmoplegia market is anticipated to expand due to the growing incidence of neurological disorders. These conditions, which involve medical issues affecting the nervous system—including the brain, spinal cord, and nerves—can manifest as muscle weakness, coordination difficulties, and cognitive impairments. The rise in neurological disorders stems from factors such as genetic predisposition, which heightens susceptibility to conditions like Alzheimer’s and Parkinson’s, and lifestyle choices, including poor diet, sedentary behavior, and chronic stress, which contribute to neurodegeneration and compromised brain function. Ophthalmoplegia is instrumental in diagnosing neurological disorders such as Alzheimer’s disease, multiple sclerosis, and stroke by highlighting impaired eye muscle control, thus indicating underlying nervous system dysfunction. For example, in March 2023, the Alzheimer’s Association, a US-based nonprofit voluntary health organization, reported that approximately 6.7 million Americans aged 65 and older were living with Alzheimer’s dementia in 2023, with projections showing this number could climb to 13.8 million by 2060. Consequently, the increasing occurrence of neurological disorders is a key driver for the growth of the ophthalmoplegia market. The ophthalmoplegia market is projected to see growth fueled by the increasing prevalence of autoimmune conditions. Autoimmune conditions are defined as disorders where the immune system mistakenly targets the body’s own healthy cells, resulting in inflammation and tissue damage. The escalating rates of autoimmune diseases are linked to certain genetic variants that can lead to an overactive immune response, making individuals more prone to attacking their own tissues. This genetic susceptibility, coupled with environmental triggers like infections, stress, and various lifestyle factors, contributes to the rising incidence of these conditions. When associated with autoimmune conditions, ophthalmoplegia treatment assists in identifying underlying immune system dysfunctions, thereby enabling targeted therapies that address both muscular paralysis and the root autoimmune disorder. As an illustration, in March 2023, according to the Society for Women’s Health Research, a U.S.-based non-profit organization, autoimmune diseases are estimated to affect 23.5 million to 50 million people. Globally, the rates of autoimmune diseases are rising by between 3 and 9 percent each year. Therefore, the growing prevalence of autoimmune conditions is boosting the ophthalmoplegia market.

How Is The Ophthalmoplegia Market Segmented Across Key Categories?

The ophthalmoplegia market covered in this report is segmented –

1) By Type: External Opthalmoplegia, Internuclear Opthalmoplegia

2) By Treatment: Surgery, Drug Treatment

3) By End-User: Hospitals, Clinics, Ambulatory Clinics

Subsegments:

1) By External Ophthalmoplegia: Chronic Progressive External Ophthalmoplegia (CPEO), Myasthenic External Ophthalmoplegia, Mitochondrial Myopathy-Associated External Ophthalmoplegia

2) By Internuclear Ophthalmoplegia: Unilateral Internuclear Ophthalmoplegia, Bilateral Internuclear Ophthalmoplegia

Who Are The Dominant Players Shaping The Ophthalmoplegia Market Landscape?

Major companies operating in the ophthalmoplegia market are Hoffmann-La Roche Ltd., AbbVie Inc., Novartis AG., Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Sun Pharmaceutical Industries Limited, Bayer AG., Santen Pharmaceutical Co. Ltd., Oculis Holding AG., Clearside Biomedical Inc., ViGeneron GmbH, GenSight Biologics SA, EyeBio Inc., Pfizer Inc., Johnson & Johnson, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb, Amgen Inc., Vertex Pharmaceuticals Inc., Acorda Therapeutics Inc., Biogen Inc., NicOx S.A.

Read the full ophthalmoplegia market report here:

https://www.thebusinessresearchcompany.com/report/ophthalmoplegia-global-market-report

Which Region Currently Holds The Largest Share Of The Ophthalmoplegia Market?

North America was the largest region in the ophthalmoplegia market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the ophthalmoplegia market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Ophthalmoplegia Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=22081&type=smp

Browse Through More Reports Similar to the Global Ophthalmoplegia Market 2026, By The Business Research Company

Ophthalmic Handheld Surgical Instruments Global Market Report

https://www.thebusinessresearchcompany.com/report/ophthalmic-handheld-surgical-instruments-global-market-report

Ophthalmic Devices Global Market Report

https://www.thebusinessresearchcompany.com/report/ophthalmic-devices-global-market-report

Diagnostic And Monitoring Ophthalmic Devices And Equipment Market

https://www.thebusinessresearchcompany.com/report/diagnostic-and-monitoring-ophthalmic-devices-and-equipment-market

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795